The world’s biggest drugs makers have pressed on in the fight against superbugs despite the pandemic, but millions of people in poorer countries, where the risk of drug-resistant infections is highest, are still missing out on key antibiotics.
A report from the Access to Medicine Foundation, an Amsterdam-based non-profit group, shows that only 54 of 166 medicines and vaccines assessed are covered by an access strategy to make them available to low- and middle-income countries.
Policies that can help poorer nations include tiered pricing, voluntary licensing agreements to boost supply, local manufacturing, technology transfers, public-private partnerships or donations.
Most of the 54 products are vaccines, anti-tuberculosis medicines, or
Read more on theguardian.com